MD Anderson Cancer Ctr. Gynecology SPORE: Uterine Cancer

描述（由申请人提供）：德克萨斯大学妇科癌症孢子的目标-医学博士。安德森癌症中心是进行创新的转化研究，预防和治疗子宫肿瘤。 在美国，发生于子宫上皮（子宫内膜）和平滑肌（子宫肌层）的肿瘤是发病率和死亡率的重要原因，但资金不足。 子宫内膜癌是美国最常见的妇科恶性肿瘤，2002年估计有39，300例新发病例和6，600例死亡。 子宫平滑肌肿瘤，尤其是平滑肌瘤，是美国子宫切除术最常见的适应症，估计每年有250，000例子宫切除术可归因于这些肿瘤。 拟议的妇科癌症孢子是一个真正的多学科计划，包括临床医生和基础科学家与肿瘤和非肿瘤背景。 这样一个多学科的团队是必要的，以实现更透彻地了解这些肿瘤的发病机制，预防和治疗。 妇科孢子由五个研究项目组成：项目1，Arzoxifene和Megace在晚期或复发性子宫内膜腺癌妇女中的随机II期比较，实验室相关性旨在确定作用机制（托马斯伯克，医学博士，和谢丽尔·步行者博士共同首席调查员）。 项目2，一种针对肥胖妇女（高危人群）的新型子宫内膜癌化学预防策略（Karen Lu，医学博士，和彼得·戴维斯医学博士哲学博士、共同主要研究者）。 项目3，子宫内膜癌的CpG岛甲基化概况（Russell布罗德斯，医学博士，哲学博士、和Jean-Pierre Issa医学博士共同主要调查员）。 项目4，子宫内膜癌的分子进展（大卫Loose-Mitchell，博士，和朱迪思·沃尔夫医学博士共同主要研究者）。 研究项目由四个核心支持：核心1，管理（托马斯·伯克，医学博士，主要研究者）;核心2，病理学（Russell布罗德斯，医学博士，哲学博士、主要研究者）;核心3，生物标志物（大卫洛斯-米切尔，博士，主要研究者）;和核心4，生物统计学和生物信息学（Peter Mueller，Ph.D.，首席研究员）。 发展研究计划（谢丽尔步行者，博士，首席研究员）将为创新研究提供资金。 职业发展计划（乔治斯坦塞尔博士，首席研究员）将鼓励教师发展研究。 内部咨询委员会和外部咨询委员会将协助科学和临床规划和项目评估。

DESCRIPTION (provided by applicant): The goal of the Gynecological Cancer SPORE at the University of Texas - M.D. Anderson Cancer Center is to conduct innovative translational research for the prevention and treatment of uterine tumors. Tumors arising from the epithelial (endometrium) and smooth muscle (myometrium) compartments of the uterus are important, yet under- funded, causes of morbidity and mortality in the United States. Endometrial cancer is the most common gynecological malignancy in the United States with an estimated 39,300 new cases and 6,600 deaths for 2002. Smooth muscle tumors of the uterus, especially leiomyomas, are the most common indication for hysterectomy in the United States, with an estimated 250,000 hysterectomies per year attributable to these tumors. The proposed Gynecological Cancer SPORE is a truly multidisciplinary program that includes clinicians and basic scientists with both oncologic and non-oncologic backgrounds. Such a multidisciplinary team is necessary to achieve a more thorough understanding of the pathogenesis, prevention, and treatment of these tumors. The Gynecologic SPORE consists of five research projects: Project 1, Randomized Phase II Comparison of Arzoxifene and Megace in Women with Advanced or Recurrent Endometrial Adenocarcinoma with Laboratory Correlates Designed to Identify Mechanism of Action (Thomas Burke, M.D., and Cheryl Walker, Ph.D., Co-Principal lnvestigator). Project 2, A Novel Endometrial Cancer Chemoprevention Strategy for Obese Women, an At-Risk Population (Karen Lu, M.D., and Peter Davies, M.D., Ph.D., Co-Principal Investigators). Project 3, CpG Island Methylation Profiling of Endometrial Cancer (Russell Broaddus, M.D., Ph.D., and Jean-Pierre Issa, M.D., Co-Principal lnvestigators). Project 4, Molecular Progression of Endometrial Cancer (David Loose-Mitchell, Ph.D., and Judith Wolf, M.D., Co-Principal Investigators). The research projects are supported by four cores: Core 1, Administration (Thomas Burke, M.D., Principal Investigators); Core 2, Pathology (Russell Broaddus, M.D., Ph.D., Principal Investigators); Core 3, Biomarkers (David Loose-Mitchell, Ph.D., Principal Investigator); and Core 4, Biostatistics and Bioinformatics (Peter Mueller, Ph.D., Principal Investigator). The Developmental Research Program (Cheryl Walker, Ph.D., Principal Investigator) will provide funding for innovative research. A Career Development Program (George Stancel, Ph.D., Principal Investigator) will encourage faculty development research. An Internal Advisory Committee and External Advisory Committee will assist in scientific and clinical planning and evaluation of projects.